$Twist Bioscience(TWST.US) fell nearly 7% on Thursday, with volume more than double the average. Q4 revenue and profit b…
$Twist Bioscience(TWST.US) fell nearly 7% on Thursday, with volume more than double the average.
Q4 revenue and profit both beat estimates, and FY2027 revenue guidance was raised to $550–560mn. The issue is structural: expected growth for its AI drug discovery segment in FY2027 is 69.2%, a significant slowdown from 175% in FY2026.
The market premium is largely driven by the AI pharma line. While the core business is stable, the high-growth segment is decelerating, forcing valuation multiples to contract. It has already dropped 20% over the past 20 trading days; future catalysts will depend on whether AI-related orders can re-accelerate next quarter.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
